Amphix Bio is a biotechnology company that develops regenerative medicine therapies using a platform of supramolecular therapeutic peptides.
Amphix Bio has raised $12.5M in total funding. The most recent round was Seed. The last funding was announced in December 2025.
Amphix Bio's investors include National Science Foundation.
Amphix Bio is headquartered in Chicago, United States.
Amphix Bio is a biotechnology company that develops regenerative medicine therapies using a platform of supramolecular therapeutic peptides.
Amphix Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amphix Bio — Funding & Investors." VCBacked, December 18, 2025, https://www.vcbacked.co/company/amphix-bio. Accessed September 30, 2026.
VCBacked. (2025). Amphix Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/amphix-bio
{{cite web |title=Amphix Bio — Funding & Investors |url=https://www.vcbacked.co/company/amphix-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated